Kaken Pharmaceutical Co., Ltd. provided consolidated financial forecast for fiscal year ending March 31, 2024. For the year, the company expects net sales of ¥73,100 million, operating profit of ¥7,600 million, profit attributable to owners of the company of ¥6,700 million and basic earnings per share of ¥176.92.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3,548 JPY | +0.80% | +2.31% | +5.75% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.75% | 855M | |
+30.38% | 684B | |
+30.00% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+15.75% | 240B | |
+9.24% | 208B | |
-7.53% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- 4521 Stock
- News Kaken Pharmaceutical Co., Ltd.
- Kaken Pharmaceutical Co., Ltd. Provides Consolidated Financial Forecast for Fiscal Year Ending March 31, 2024